Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia.
OBJECTIVE
This study was conducted to explore the association between nonalcoholic fatty liver disease and glucose metabolism as well as insulin resistance using the homeostasis model assessment method (HOMA).


METHODS
From July 2003 to June 2004, 23 patients with ultrasound-proved fatty liver and either normal (10 patients) or abnormal (13 patients) serum aminotransferase levels were enrolled. Blood tests included a routine biochemistry, a 75-g glucose oral glucose tolerance test (OGTT) with blood sampled at 30-minute intervals during a 120-minute period. Fasting and 120-minute serum leptin, insulin, and C-peptide concentrations were also measured.


RESULTS
Using the Mann-Whitney U test, significant differences were found in gamma glutamyl transpeptidase (28.6+/-7.9 vs. 65.1+/-65.9 U/L, P=0.008), fasting insulin (FI) (13.11+/-7.53 vs. 31.76+/-42.95 muU/mL, P=0.02), fasting C-peptide (3.82+/-3.00 vs. 2.17+/-0.43 ng/mL, P=0.01), fasting leptin (10.34+/-4.05 vs. 24.27+/-24.97 ng/mL, P=0.01), HOMA-IR (3.34+/-1.06 vs. 8.81+/-13.18, P=0.02), and HOMA beta-cell function (120.32+/-52.50 vs. 242.20+/-247.29, P=0.02) between normal and abnormal ALT/AST function groups. From the 75-g OGTT, no significant difference of plasma glucose was noted at 0, 30, 60, and 90 minutes but significant change was noted in 120-minute plasma glucose (99.3+/-21.5 vs. 131.4+/-27.3 mg/dL, P=0.004) of 2 groups.


CONCLUSIONS
In conclusion, patients with fatty liver proved by ultrasound sonography might be at high risk of developing type 2 diabetes, especially when they had elevated liver enzymes. OGTT is warranted for the early diagnosis of these high risk patients.
Su
Ching-Chieh
CC
Division of Endocrinology and Metabolism, Department of Internal Medicine, Cardinal Tien Hospital, Taipei, Taiwan. suk.ccsu@msa.hinet.net
Wang
Kun
K
Hsia
Te-Lin
TL
Chen
Ching-Shuen
CS
Tung
Tao-Hsin
TH
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002096:C-Peptide / Q000097:blood; D005234:Fatty Liver / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging; D005260:Female; D005508:Food Deprivation; D005951:Glucose Tolerance Test; D006706:Homeostasis; D006801:Humans; D006943:Hyperglycemia / Q000097:blood* / Q000150:complications / Q000473:pathology; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D019518:Postprandial Period; D014463:Ultrasonography
D015415:Biomarkers; D002096:C-Peptide; D007328:Insulin; D020738:Leptin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase